Nicolo Zangirolami / Shutterstock.com
An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Sobolev of Rouse.
The Russian IP ombudsman Anatoly Semenov has written to the Russian lower house, the State Duma, drawing its attention to the increasing number of patent conflicts among pharmaceutical manufacturers in Russia and urged the Duma to legislate to address the issue.
According to Semenov, there are no clear-cut criteria for assessing the validity of so-called ‘secondary patents’ seeking protection that extends beyond the original active ingredient. As a result, foreign companies try various means to extend patent protection by patenting some new aspects thereof. They often succeed, despite such new patents being of questionable validity.
The Russian Federal Service for IP (Rospatent) approves more than 75% of patent applications, whereas in other countries it is only 50%. Thus, if no measures are taken, foreign companies will be obtaining more and more new patents for known drugs which they can then use to prevent Russian generics companies producing them. This could quickly lead to the bankruptcy of a number of Russian pharmaceutical companies, many of which are generics manufacturers rather than researchers or innovators.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Rouse, ombudsman, validity, Russia IP, State Duma, patent protection, Rospatent, innovation, generics manufacturers, brands, exclusive rights, prior use
